T0	Outcomes 85 128	exudative age-related macular degeneration.
T1	Outcomes 977 1005	best-corrected visual acuity
T2	Outcomes 1095 1137	number of ranibizumab injections required.
T3	Outcomes 1156 1205	6-month change in central macular thickness (CMT)
T4	Outcomes 1447 1465	no adverse effects
T5	Outcomes 1538 1561	the efficacy and safety
T6	Outcomes 1779 1791	reducing CMT